Korro Bio, Inc. · NASDAQ:KRRO
Korro Bio — Investor Presentation (May 2026)
5 slides from Korro Bio's investor presentation, May 19, 2026
Slide 1: 2026 Corporate Presentation
Exhibit 99.2 March May 2025 2026 Corporate Presentation 11
Slide 2: Forward-Looking Statement and Disclaimers
Forward-Looking Statement and Disclaimers Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to,
Slide 3: Positioned for Value Creation in 2026 and Beyond
Positioned for Value Creation in 2026 and Beyond KRRO-111 Development Candidate (DC) nominated for GalNAc- conjugated alpha-1 antitrypsin deficiency (AATD) program Regulatory filing for KRRO-121 anticipated in H2 2026 DC expected for a 3rd GalNAc-conjugated liver asset in H2 2026 Cash runway into H2
Slide 4: KRRO-111, a GalNAc-conjugated RNA Editing Oligo, Demonstrated >90% Editing and ~90% M-AAT Protein In Vivo
KRRO-111, a GalNAc-conjugated RNA Editing Oligo, Demonstrated >90% Editing and ~90% M-AAT Protein In Vivo GalNAc KRRO-111 SERPINA1 RNA Editing % M-AAT Protein 100 91.8 100 84.3 M-AAT Dosing: Q2Dx3 at 5 or 10 mg/kg Proportion (%) Z-AAT 80 80 % Editing 60 60 NSG-PiZ Mouse Week 0 1 40 40 20 20 Day 7: s
Slide 5: KRRO-111 Nearly Eliminates Active Z Protein Production and Drives Progressive Clearance of Pre-existing Aggregates In Vivo
KRRO-111 Nearly Eliminates Active Z Protein Production and Drives Progressive Clearance of Pre-existing Aggregates In Vivo Elimination of Active Z-AAT Protein Production and Progressive Clearance of Pre-existing Aggregates Near-Complete Cessation Robust Reduction of Pre- Vehicle Control KRRO-111 of